03/12/2025
On the International Day of Persons with Disabilities, we reaffirm our commitment to patient‑centric innovation that reduces barriers to safe, effective medicine use.
Accessible oral dose design: We invest in orally disintegrating and 'mouth‑melt tablet's that dissolve without water, supporting patients with dysphagia, neuromuscular conditions, or limited mobility.
Liquid and flexible formulations: Age‑ and ability‑appropriate liquids and suspensions enable precise dose titration for children, older adults, and those unable to swallow conventional tablets.
Usability‑led packaging: By focusing on easy‑open, intuitive packaging and clear labelling, we align with universal design principles and support patients with limited grip strength or visual impairment.
In clinical development, disability inclusion cannot be an afterthought. Evidence shows that people with disabilities are frequently excluded from trials through broad or poorly justified criteria, despite being part of the real‑world treatment population.
Lyrus advocates for and supports more inclusive clinical trial designs that:
Avoid using disability itself as an exclusion criterion when not scientifically justified.
Incorporate reasonable accommodations, accessible materials, and adaptive protocols so that eligible participants with disabilities can take part safely and meaningfully.
Through Think. Design. Deliver., Lyrus is working to ensure that accessibility is built into our formulations, packaging, and development pathways—so that medicines are not only effective in trials, but usable and safe for people with diverse abilities in everyday life.
